Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy (Q38773023)

6 September 2017

Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy (English)

1 reference

6 September 2017

1 reference

coronary artery disease

1 reference

based on heuristic

inferred from title

author

Arnold von Eckardstein

series ordinal

2

object named as

Arnold von Eckardstein

1 reference

6 September 2017

Wijtske Annema

1

1 reference

6 September 2017

24 February 2016

1 reference

6 September 2017

Translational Research

1 reference

6 September 2017

173

1 reference

6 September 2017

30-57

1 reference

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials

6 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Major lipids, apolipoproteins, and risk of vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Mouse models of disturbed HDL metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Therapeutic applications of reconstituted HDL: When structure meets function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Structure of HDL: particle subclasses and molecular components.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL and atherothrombotic vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein reduces the human monocyte inflammatory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI: role of negatively charged phospholipids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Dysfunctional HDL: from structure-function-relationships to biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Heart failure is associated with impaired anti-inflammatory and antioxidant properties of high-density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Impaired cholesterol efflux capacity and vasculoprotective function of high-density lipoprotein in heart transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Altered composition of HDL3 in FH subjects causing a HDL subfraction with less atheroprotective function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL cholesterol efflux capacity and incident cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The HDL proteome in acute coronary syndromes shifts to an inflammatory profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Role of Serum Amyloid A During Metabolism of Acute-Phase HDL by Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL in humans with cardiovascular disease exhibits a proteomic signature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: the Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Qualitative characteristics of HDL in young patients of an acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Unraveling the complexities of the HDL lipidome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Enhanced efflux of cholesterol from ABCA1-expressing macrophages to serum from type IV hypertriglyceridemic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Enhanced removal of cholesterol from macrophage foam cells to serum from type IV hypertriglyceridemic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Postprandial lipemia enhances the capacity of large HDL2 particles to mediate free cholesterol efflux via SR-BI and ABCG1 pathways in type IIB hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Serum levels of high-density lipoprotein phospholipids correlate inversely with severity of angiographically defined coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The significance of serum HDL phospholipid levels in angiographically defined coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Functions of plasmalogen lipids in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Delay of copper-catalyzed oxidation of low density lipoprotein by in vitro enrichment with choline or ethanolamine plasmalogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Apolipoprotein M modulates erythrocyte efflux and tubular reabsorption of sphingosine-1-phosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

MicroRNA-223 coordinates cholesterol homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Prognostic value of myeloperoxidase in patients with chest pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Diagnostic and prognostic performance of myeloperoxidase plasma levels compared with sensitive troponins in patients admitted with acute onset chest pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

An abundant dysfunctional apolipoprotein A1 in human atheroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Protein carbamylation and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Protein carbamylation links inflammation, smoking, uremia and atherogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Protein carbamylation renders high-density lipoprotein dysfunctional

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anti-apolipoprotein A-1 IgG levels predict coronary artery calcification in obese but otherwise healthy individuals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Niacin: a long history, but a questionable future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Combined statin and niacin therapy remodels the high-density lipoprotein proteome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Extended-release niacin or ezetimibe and carotid intima-media thickness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effects of extended-release niacin with laropiprant in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effects of combination lipid therapy in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Combination therapy in dyslipidemia: where are we now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Fibrate treatment induced quantitative and qualitative HDL changes associated with an increase of SR-BI cholesterol efflux capacities in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effect of torcetrapib on the progression of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effects of torcetrapib in patients at high risk for coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Safety of anacetrapib in patients with or at high risk for coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japanese-american men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Unique lipoprotein phenotype and genotype associated with exceptional longevity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Evidence from case-control and longitudinal studies supports associations of genetic variation in APOE, CETP, and IL6 with human longevity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Association of cholesteryl ester transfer protein (CETP) gene polymorphism, high density lipoprotein cholesterol and risk of coronary artery disease: a meta-analysis using a Mendelian randomization approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-Density Lipoprotein-Targeted Therapy and Apolipoprotein A-I Mimetic Peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein restores endothelial function in hypercholesterolemic men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Non-clinical development of CER-001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Reproducibility and biological variability of HDL's vascular functional assays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Benchmarks for the assessment of novel cardiovascular biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Biomarkers of cardiovascular disease: molecular basis and practical considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Did we abandon probucol too soon?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

Androgens and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2016.02.008

10.1016/J.TRSL.2016.02.008

7 January 2021

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

26972566